In 2017, the first K-Ras(G12D)-selective inhibitory peptide KRpep-2d was reported11–13, and subsequently demonstrated to reversibly bind K-Ras(G12D) and suppress in vitro proliferation of human A427 lung carcinoma cells expressing K-Ras(G12D). This evidence concerns the gene KRAS and lung carcinoma.